Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: UK stocks sink on fears over Scottish referendum, Ukraine

Mon, 08th Sep 2014 11:36

Concerns surrounding the upcoming referendum on Scottish independence and a fragile ceasefire agreement in Ukraine were weighing heavily on UK stocks on Monday.London's FTSE 100 was trading down 1% at 6,789 by midday. The index has not closed below the 6,800 mark since 22 August when it settled at 6,775.25.The pound was trading at a 10-month low as the ‘yes’ campaign for Scottish independence gathered steam, with supporters for the break-up taking a narrow lead in a Yougov pool just 10 days before the vote. This was the first lead for the 'yes' lead since the campaign began.Businesses with large Scottish exposure were also rocked by the increased support for independence, with their shares suffering steep falls in morning trading."One could also question how much store we can put in a single poll. For now, the markets are certainly beginning to price in what was deemed unthinkable," said market strategist Brenda Kelly from IG Group.In other news, Ukraine and Russia accused each other of violating the ceasefire that was agreed on Friday, as shelling and gunfire in east Ukraine resumed on Sunday.The city of Mariupol, where a woman was killed on Sunday night, remains in Ukrainian hands but reports say the town on the Sea of Azov could soon come under assault from pro-Russian rebels. Blasts were also heard in Donetsk with both parties reciprocally accusing each other of firing first and threatening the truce.AB Foods and financials in the redFood, ingredients and retail group Associated British Foods fell despite reiterating its guidance for profit growth in the year to 13 September. AB Foods said that strong profit performances from the Primark and grocery divisions and an improvement in ingredients are expected to offset the adverse effect of lower sugar prices and the £50m impact from the recent strength in sterling.Banking and financial stocks were under pressure as investors speculated about how an independent Scotland could affect business. Lloyds, RBS and Standard Life were unwanted, along with utility firm SSE.RBS was also falling heavily after Credit Suisse listed it as one of its "key underperforms" in the European banking sector. HSBC and Standard Chartered were also rated 'underperform'.Glaxosmithkline was trading lower after Credit Suisse slashed its earnings forecasts for the company and trimmed its target price from 1,475p to 1,400p. The bank kept an 'underperform' rating for the stock, saying that it trades at a 10% premium to others in the sector.De La Rue gained after being named preferred bidder for a 10-year contract to print bank notes for the Bank of England from April 2015.Veterinary drugs firm Dechra Pharmaceuticals was also higher after a turnaround in the second half helped full-year revenues to rise 1.6%. The company also said underlying profits jumped 18% as it hiked its dividend by 10%.Market MoverstechMARK 2,828.65 -0.96%FTSE 100 6,788.67 -0.97%FTSE 250 15,702.50 -1.39%FTSE 100 - RisersRandgold Resources Ltd. (RRS) 4,772.00p +0.74%Mondi (MNDI) 1,052.00p +0.67%ARM Holdings (ARM) 960.00p +0.37%Tesco (TSCO) 229.25p +0.33%easyJet (EZJ) 1,370.00p +0.29%Burberry Group (BRBY) 1,496.00p +0.27%Shire Plc (SHP) 5,035.00p +0.20%Glencore (GLEN) 367.25p +0.07%FTSE 100 - FallersAssociated British Foods (ABF) 2,761.00p -5.09%Babcock International Group (BAB) 1,052.00p -4.97%Lloyds Banking Group (LLOY) 71.59p -3.26%Royal Bank of Scotland Group (RBS) 336.00p -3.17%Standard Life (SL.) 403.70p -3.07%Persimmon (PSN) 1,297.00p -2.85%SSE (SSE) 1,472.00p -2.58%Weir Group (WEIR) 2,649.00p -2.57%BAE Systems (BA.) 444.20p -2.54%Ashtead Group (AHT) 1,000.00p -2.34%FTSE 250 - RisersDe La Rue (DLAR) 770.00p +3.63%Supergroup (SGP) 1,223.00p +1.92%Dechra Pharmaceuticals (DPH) 745.00p +1.92%Fidelity China Special Situations (FCSS) 120.50p +1.69%Centamin (DI) (CEY) 66.80p +1.52%Templeton Emerging Markets Inv Trust (TEM) 624.00p +1.22%JPMorgan Emerging Markets Inv Trust (JMG) 605.00p +1.17%Genesis Emerging Markets Fund Ltd Ptg NPV (GSS) 577.00p +1.05%Polar Capital Technology Trust (PCT) 499.50p +1.01%JPMorgan American Inv Trust (JAM) 262.50p +0.88%FTSE 250 - FallersOcado Group (OCDO) 300.50p -5.56%Galliford Try (GFRD) 1,218.00p -4.47%Hochschild Mining (HOC) 162.00p -4.20%Brewin Dolphin Holdings (BRW) 276.30p -4.20%Diploma (DPLM) 654.00p -4.18%Debenhams (DEB) 64.45p -4.09%Ophir Energy (OPHR) 225.30p -3.84%Bellway (BWY) 1,530.00p -3.83%Exova Group (EXO) 180.70p -3.68%Morgan Advanced Materials (MGAM) 305.90p -3.62%
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.